Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pardeep Kumar

Internal Medicine Terre Haute, IN Medical Doctor

NPI 1336251354 CMS profile 105608

420 E Hospital Ln, Terre Haute, IN 47802

Open in the dashboard

General payments

$12,983

830 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pardeep Kumar of Terre Haute, IN is reported in the CMS Open Payments database as having received $12,983 across 830 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,599 138
2024 General $2,401 141
2023 General $2,009 127
2022 General $1,743 117
2021 General $1,002 70
2020 General $972 68
2019 General $2,258 169

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pardeep Kumar
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Pardeep Kumar were reported at $2,599. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Pardeep Kumar Internal Medicine median Middle half National median
2019 $2,258 $159 $48–$570 $163
2020 $972 $119 $33–$402 $114
2021 $1,002 $135 $37–$521 $132
2022 $1,743 $141 $42–$496 $149
2023 $2,009 $149 $45–$519 $160
2024 $2,401 $154 $47–$537 $164
2025 $2,599 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,413 107 payments
  2. AstraZeneca Pharmaceuticals LP $1,216 74 payments
  3. Lilly USA, LLC $1,162 90 payments
  4. AbbVie, Inc. $1,030 62 payments
  5. Novartis Pharmaceuticals Corporation $903 52 payments
  6. Corcept Therapeutics $895 49 payments
  7. Amgen Inc. $756 47 payments
  8. Pfizer Inc. $670 46 payments
  9. GlaxoSmithKline, LLC. $482 44 payments
  10. Sanofi-Aventis U.S. LLC $310 22 payments
  11. Other $4,146 237 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,858 822 payments
  2. Education $125 8 payments
Products named General payments · program years 2019–2025
  1. Korlym $895 49 payments
  2. FARXIGA $649 36 payments
  3. Ozempic $614 44 payments
  4. RYBELSUS $539 37 payments
  5. LEQVIO $516 26 payments
  6. Otezla $489 31 payments
  7. MOUNJARO $448 26 payments
  8. UBRELVY $430 28 payments
  9. Repatha $399 24 payments
  10. ENTRESTO $392 20 payments
  11. Other $11,550 765 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 146 drugs

Part D claims

8,034

Median for Internal Medicine: 777

Drug cost

$971,292

Median for Internal Medicine: $73,373

Branded share of claims

28.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 257 $272,631
Ozempic Semaglutide Brand 192 $192,723
Eliquis Apixaban Brand 146 $82,630
Jardiance Empagliflozin Brand 103 $64,519
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 64 $43,211
Tradjenta Linagliptin Brand 56 $39,897
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 16 $25,873
Trulicity Dulaglutide Brand 21 $25,116
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 34 $22,405
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 17 $17,615

The 10 drugs with the highest cost, of 146 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$69,585

Of which drugs: $1,476

Medicare patients

220

Average age 71

Services billed

1,342

111 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 46%
Depression 42%
Arthritis 39%
Ischemic heart disease 38%
Alzheimer's or dementia 32%
Chronic kidney disease 30%
COPD 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 16 16 $1,309
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 79 $52

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
$222 — —
FARXIGA
$175 — —
TRELEGY ELLIPTA
$142 64 —
ZEPBOUND
$121 — —
MOUNJARO
$117 257 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

830 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record